Review
Ophthalmology
John Yu Cheng, Curtis E. Margo
Summary: The Food and Drug Administration has licensed and approved numerous vaccines since 2010, but ocular adverse events can still occur. Common reactions include eyelid and conjunctival issues, while more serious adverse events such as optic neuritis and intraocular inflammation have also been reported.
SURVEY OF OPHTHALMOLOGY
(2022)
Article
Immunology
Ates Kara, Aslihan Coskun, Fehminaz Temel, Pervin Ozelci, Selmur Topal, Ihsan Ates
Summary: The study investigated the distribution and severity of allergic adverse events following the administration of the TURKOVAC (TM) COVID-19 vaccine in 15 provinces in Turkiye. The results showed that only 0.5% of participants reported experiencing an allergic reaction, with 8.5% receiving medical treatment. Male participants had a higher prevalence of allergic reactions. Among all participants, 4.4% reported a history of allergy, with drugs being the most common allergens. Overall, the TURKOVAC (TM) vaccine has a low rate of allergic reactions and can be an alternative to other COVID-19 vaccines.
Article
Immunology
Laura Bonzano, Olivera Djuric, Pamela Mancuso, Lidia Fares, Raffaele Brancaccio, Marta Ottone, Eufemia Bisaccia, Massimo Vicentini, Alessia Cocconcelli, Alfonso Motolese, Rostyslav Boyko, Paolo Giorgi Rossi, Alberico Motolese
Summary: An audit in Italy examined the risk assessment and occurrence of adverse events (AEs) in individuals receiving COVID-19 vaccines, finding that the majority of AEs were non-serious and non-allergic. While vaccination in a protected setting may reduce the incidence of AEs, a history of allergies and other anamnestic information are not reliable predictors of vaccine-related AEs in the general population.
Article
Immunology
Abdulellah M. Almohaya, Haya Alsubie, Bader Alqarni, Bashayer Alzayad, Ali Alghar, Khalid Alshahrani, Mazin Barry
Summary: This study aims to explore the nature and outcome of adverse events following the administration of BNT162B2 vaccine in a community vaccination center in Riyadh, Saudi Arabia. The results showed that acute adverse events were rare and mostly non-serious, with a higher occurrence rate in women.
Review
Allergy
Krzysztof Rutkowski, Rita Mirakian, Stephen Till, Ryszard Rutkowski, Annette Wagner
Summary: COVID-19 vaccines can reduce severity of infection and prevent deaths, but limited data on triggers and mechanisms of anaphylaxis exist. Therefore, we propose an innovative allergy support model and practical investigation algorithm for anaphylaxis to these vaccines.
CLINICAL AND EXPERIMENTAL ALLERGY
(2021)
Article
Medicine, General & Internal
Aditi Halder, Hanaho Imamura, Stewart Condon, Kelly Boroughs, Sven C. Nilsson, Teresa Anderson, Ian D. Caterson
Summary: This study reports on the safety of the Pfizer/BioNtech BNT162b2 vaccine in an Australian vaccination clinic and shows low rates of adverse reactions post-vaccination. Results also suggest possible predisposing factors for rare allergic reactions to the vaccine.
INTERNAL MEDICINE JOURNAL
(2022)
Article
Immunology
Ayako Kumabe, Tsuneaki Kenzaka, Shinsuke Yahata, Ken Goda, Masanobu Okayama
Summary: This study investigated the influence of sex, age, and vaccination history on adverse reactions (ARs) to influenza vaccines and their relationship with the risk of influenza infection. The results showed that men and individuals aged >= 60 years were less likely to experience ARs, while those with a history of influenza vaccination had a higher likelihood of ARs. Individuals with ARs, especially localized ones, were more likely to contract influenza infection.
Review
Allergy
Kristen B. Corey, Grace Koo, Elizabeth J. Phillips
Summary: After more than 1 year since the first COVID-19 vaccines were rolled out, 572 million doses have been administered in the United States. Adverse effects have been rare, and the more serious the effect, the less frequent its occurrence. However, there are almost no true contraindications to COVID-19 vaccination, and most individuals recover without further complications. This review offers guidance to allergists/immunologists on appropriate next steps based on patients' allergy history or adverse reactions to ensure safe global immunization.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Article
Public, Environmental & Occupational Health
Ran Hu, Shanshan Peng, Yuanbao Liu, Fengyang Tang, Zhiguo Wang, Lei Zhang, Jun Gao, Hongxiong Guo
Summary: This study aimed to describe the incidence and characteristics of adverse events following immunization in Jiangsu province of China from 2015 to 2018. The sensitivity of AEFI monitoring in Jiangsu Province is increasing and higher than the national average and most countries. The majority of AEFI cases were common adverse reactions, while the serious vaccine reactions caused by vaccines were extremely low.
Review
Virology
Katrin Hartmann, Herman Egberink, Karin Moestl, Diane D. Addie, Sandor Belak, Corine Boucraut-Baralon, Tadeusz Frymus, Albert Lloret, Regina Hofmann-Lehmann, Fulvio Marsilio, Maria Grazia Pennisi, Severine Tasker, Etienne Thiry, Uwe Truyen, Margaret J. Hosie
Summary: Vaccine-associated adverse events (VAAEs), such as feline injection-site sarcomas (FISSs), are rare but can be severe. The European Advisory Board on Cat Diseases (ABCD) provides a comprehensive review on VAAEs in cats, summarizing existing knowledge and filling gaps with expert opinions. The causes of VAAEs include immune reactions, local reactions, administration errors, and manufacturing failures. FISS, the most severe VAAE, can occur after vaccinations or other injections. It is important to understand and minimize the risks associated with vaccination.
Review
Immunology
Alexander T. Gallo, Lisa Scanlon, Jade Clifford, Lawson Patten-Williams, Lachlan Tweedie, Dani Li, Sandra M. Salter
Summary: This study retrospectively reviewed immediate adverse events following COVID-19 vaccination in 314 community pharmacies in Australia between July 2021 and June 2022. The most common adverse reaction observed was syncope, and pharmacists appropriately and comprehensively managed both serious and non-serious adverse events.
Review
Allergy
Anne Des Roches, Francois Graham, Philippe Begin, Louis Paradis, Michael Gold
Summary: The development and widespread use of vaccines have significantly impacted public health by preventing morbidity and mortality from infectious diseases. Most people tolerate vaccines well, and healthcare providers play a critical role in maintaining public confidence in vaccines.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Allergy
Emilia Anis, Sharon Alroy Preis, Noa Cedar, Yuval Tal, Isca Hershkowitz, Alon Y. Hershko
Summary: A study conducted in Israel investigated allergic reactions to COVID-19 vaccines and found that reporting of allergies decreased over time and did not affect vaccine adherence. A history of allergies may affect reporting profiles but not the occurrence of vaccine allergy.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Article
Medicine, General & Internal
Nicola P. Klein, Ned Lewis, Kristin Goddard, Bruce Fireman, Ousseny Zerbo, Kayla E. Hanson, James G. Donahue, Elyse O. Kharbanda, Allison Naleway, Jennifer Clark Nelson, Stan Xu, W. Katherine Yih, Jason M. Glanz, Joshua T. B. Williams, Simon J. Hambidge, Bruno J. Lewin, Tom T. Shimabukuro, Frank DeStefano, Eric S. Weintraub
Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Dermatology
Mohammad Reza Pourani, Mohammad Shahidi Dadras, Mehri Salari, Reem Diab, Nastaran Namazi, Fahimeh Abdollahimajd
Summary: This study evaluated the possible side effects of COVID-19 vaccines in the Iranian population, finding that 30% of individuals experienced cutaneous reactions, with focal injection site reaction, exanthematous rash, and urticaria being the most common. Rare cutaneous adverse events included vesicular eruption, pernio-like lesions, angioedema, erythema multiforme-like eruption, and zoster. Familiarizing physicians with these complications can aid in their detection and management while introducing them to individuals may increase acceptance of vaccine-related adverse effects.
DERMATOLOGIC THERAPY
(2022)